Clik here to view.
Pulmatrix shares soar after winning FDA designation
Pulmatrix (NSDQ:PULM) shares were up 159% to $1.79 apiece in mid-afternoon trading today after the company announced that its drug candidate for treating fungal infections in the lungs of cystric...
View ArticleClik here to view.
Allergan pays $15m for failing to disclose Actavis ‘white knight’ offer
The SEC said yesterday that Allergan (NYSE:AGN) will pay a $15 million fine for failing to disclose its 2014 merger talks with Actavis. In June 2014, Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX) offered...
View ArticleClik here to view.
Sanofi’s Suliqua combination therapy approved in European Union
Sanofi (NYSE:SNY) said today that the European Commission granted marketing authorization in Europe for its Suliqua combination product for adults with type II diabetes. The therapy is a fixed-ratio...
View ArticleClik here to view.
FDA issues guidance for off-label communications for drugs & devices
The FDA issued 2 draft guidances today to clarify the federal watchdog’s recommendations for communications regarding medical products, including off-label information and communicating...
View ArticleClik here to view.
Donald Trump: 5 questions medtech needs to ask
[Image courtesy of Zach Rudisin, CC BY-SA 3.0]From tax breaks to Obamacare repeal, medtech companies are likely due to experience major changes under President Donald Trump. The situation, though,...
View ArticleClik here to view.
Researchers develop responsive, insulin-releasing skin patch
Researchers from the University of North Carolina at Chapel Hill, North Carolina State University and Changchun Institute of Applied Chemistry at the Chinese Academy of Sciences have developed a skin...
View ArticleClik here to view.
Study finds financial ties between researchers, industry associated with...
A study conducted by a team of U.S. researchers found that financial ties between researchers and the companies that make the drugs they are studying are independently associated with positive trial...
View ArticleClik here to view.
Cytori buys Azaya’s nanoparticle tech in stock deal
Cytori Therapeutics (NSDQ:CYTX) said this week that it bought San Antonio-based Azaya Therapeutics and its nanoparticle cancer drugs in a stock deal. Azaya shareholders will receive $2 million in CTYX...
View ArticleClik here to view.
Kaleo announces US availability, pricing of allergy auto-injector
Kaléo Inc. said yesterday that its Auvi-Q epinephrine auto-injector will be available by prescription in the U.S. beginning Feb. 14th. The Richmond, Virginia-based company’s emergency allergy treatment...
View ArticleClik here to view.
Abbott touts study showing SCS helps curb opioid use in chronic pain patients
Abbott (NYSE:ABT) touted data from a 5,400 patient study evaluating daily opioid use following spinal cord stimulation therapy in patients with chronic pain. The researchers found that average daily...
View ArticleClik here to view.
Ocular Therapeutix resubmits NDA for Dextenza
Ocular Therapeutix (NSDQ:OCUL) said today that it resubmitted a New Drug Application to the FDA for its post-surgical ocular pain reliever. The hydrogel plug, inserted into a patient’s tear duct, is...
View ArticleClik here to view.
Ocular Therapeutix looks to raise $25m in public offering
Ocular Therapeutix (NSDQ:OCUL) said today that it launched a $25 million underwritten public offering of its common stock. The Bedford, Mass.-based company did not provide any specific pricing details...
View ArticleClik here to view.
FDA approves 2mg Narcan nasal spray for opioid overdose treatment
Adapt Pharma said today that the FDA approved the 2mg formulation of its Narcan nasal spray for the emergency treatment of opioid overdose. The 2mg dose is intended for opioid-dependent patients that...
View ArticleClik here to view.
InSitu Biologics touts preclinical data for non-opiate hydrogel painkiller
InSitu Biologics touted preclinical data for its non-opiate, hydrogel-based painkiller, AnestaGel, for use in peri-operative regional pain management. The St. Paul, Minn.-based company designs...
View ArticleClik here to view.
Microscopic submarines release drugs depending on acid concentration
Researchers have developed tiny ‘submarines’ that speed through the stomach using gastric acid for fuel. The proton-driven micromotors have a pH-sensitive polymer coating that can be loaded with drugs...
View ArticleClik here to view.
Johnson & Johnson to pay $30B for Actelion
After weeks of exclusive negotiations, Johnson & Johnson (NYSE:JNJ) said on Thursday that it plans to buy Swiss biotech firm Actelion (VTX:ATLN) for $30 billion in an all-cash deal. The companies...
View ArticleClik here to view.
Biogen beats Q4 earnings, misses on full-year rev forecast
Shares in Biogen (NSDQ:BIIB) rose this week after the biopharmaceutical company met expectations on Wall Street with its 4th quarter financial results, but pegged its full-year revenue forecast lower...
View ArticleClik here to view.
Report: Novartis eyes sale for Alcon lens business
Novartis (NYSE:NVS) said yesterday that it is considering selling its Alcon eye care business and will buy back up to $5 billion worth of shares over the next 12 months, in an effort to reorganize...
View ArticleClik here to view.
Johnson & Johnson’s earnings disappoint, but pharma rev climbs
Shares in Johnson & Johnson (NYSE:JNJ) fell this week after the company missed the consensus top-line forecasts but pulled off earnings beats for both the 4th quarter and 2016. Pharmaceutical sales...
View ArticleClik here to view.
Endo cuts staff in restructuring effort
Endo International (NSDQ:ENDP) said today that it will cut 90 full-time positions from its workforce in an effort to restructure its generics and U.S. branded pharmaceutical businesses. The company...
View Article